Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Chronic kidney disease (CKD) is defined by a low glomerular filtration rate or high
albuminuria, and affects 15–20% of adults globally. CKD increases the risk of various …
albuminuria, and affects 15–20% of adults globally. CKD increases the risk of various …
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
CE Ndumele, J Rangaswami, SL Chow, IJ Neeland… - Circulation, 2023 - Am Heart Assoc
Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors,
chronic kidney disease, and the cardiovascular system and has profound impacts on …
chronic kidney disease, and the cardiovascular system and has profound impacts on …
Sex differences in type 2 diabetes
A Kautzky-Willer, M Leutner, J Harreiter - Diabetologia, 2023 - Springer
The prevalence of type 2 diabetes mellitus is increasing in both sexes, but men are usually
diagnosed at a younger age and lower body fat mass than women. Worldwide, an estimated …
diagnosed at a younger age and lower body fat mass than women. Worldwide, an estimated …
A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease
C Delgado, M Baweja, DC Crews… - Journal of the …, 2021 - journals.lww.com
Background In response to a national call for re-evaluation of the use of race in clinical
algorithms, the National Kidney Foundation (NKF) and the American Society of Nephrology …
algorithms, the National Kidney Foundation (NKF) and the American Society of Nephrology …
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes …
IH de Boer, K Khunti, T Sadusky, KR Tuttle… - Diabetes …, 2022 - Am Diabetes Assoc
People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure,
atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent …
atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent …
National trends in use of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists by cardiologists and other specialties, 2015 to …
Background Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) and glucagon‐like
peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type …
peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type …
[HTML][HTML] Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US
Importance Randomized clinical trials have shown that glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) cause significant weight loss and reduce cardiovascular events in …
agonists (GLP-1 RAs) cause significant weight loss and reduce cardiovascular events in …
Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 1999-2020
Importance Individually, cardiac, renal, and metabolic (CRM) conditions are common and
leading causes of death, disability, and health care–associated costs. However, the …
leading causes of death, disability, and health care–associated costs. However, the …
Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care?
Given the high risk of adverse outcomes in patients with heart failure and reduced ejection
fraction (HFrEF), there is an urgent need for the initiation and titration of guideline-directed …
fraction (HFrEF), there is an urgent need for the initiation and titration of guideline-directed …
Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the Veterans Health …
Importance Novel therapies for type 2 diabetes can reduce the risk of cardiovascular
disease and chronic kidney disease progression. The equitability of these agents' …
disease and chronic kidney disease progression. The equitability of these agents' …